Bile salt hydrolase (BSH) enzymes are widely expressed by human gut bacteria and catalyze the 18 gateway reaction leading to secondary bile acid formation. Bile acids regulate key metabolic and 19 immune processes by binding to host receptors. There is an unmet need for a potent tool to 20 inhibit BSHs across all gut bacteria in order to study the effects of bile acids on host physiology. 21
Introduction 30
Bile acids, long relegated to the role of undistinguished detergents, have recently 31 emerged as likely candidates for the molecular messengers that allow members of the human gut 32 microbiome to modulate the physiology and behavior of their hosts.
1,2 Investigating these 33 potential roles in detail has been hampered by the lack of tools to regulate specific messages, and 34 developing the appropriate tools has been hampered in turn by the complex biosynthesis of bile 35 acids. Primary bile acids are produced in the liver from cholesterol and conjugated to taurine or 36 glycine to produce primary conjugated bile acids (Fig. 1a) . These molecules are stored in the 37 gallbladder and released into the digestive tract where they aid in absorption of lipids and fat-38 soluble vitamins. Over 95% of bile acids are reabsorbed in the ileum and transported to the liver. 39
The remaining ~5% pass into the colon, where the majority of gut bacteria reside. Gut bacteria 40 then enzymatically modify these primary bile acids, producing a group of molecules called 41 secondary bile acids (Fig. 1a) . Roughly 50 secondary bile acids have been detected in human 42 feces, and their concentrations can reach low millimolar levels.
3,4

43
Bile acids, which share a carbon skeleton with steroids, can bind to host receptors, 44 including nuclear hormone receptors (NhR) and G-protein coupled receptors (GPCRs). By acting 45 as either agonists or antagonists for these receptors, bile acids regulate host metabolism, 46 including energy expenditure and glucose and lipid homeostasis, 2,5 and host immune response, 47 including both innate and adaptive immunity.
6,7 Dysregulated bile acid metabolism is thought to 48 play causal roles in the pathophysiology of diseases including hypercholesterolemia, obesity, 49 diabetes, cancer, and gallstone formation, 2, 8, 9 further highlighting the biological importance of 50 these molecules. 51
The key reaction in the conversion of primary into secondary bile acids is the hydrolysis 52 of the C24-amide bond of conjugated primary bile acids (Fig. 1a) . This enzymatic conversion is 53 production of trimethylamine N-oxide and display minimal off-target effects. 13 This work 78
demonstrates that covalent inhibitors of bacterial enzymes can be effective in the gut, thus 79 further validating our approach. 80
While there is significant divergence in BSH protein sequence across gut strains, all BSHs 81 possess a conserved active site that includes a catalytic cysteine (Cys2). 1, 10 This residue performs 82 the nucleophilic attack on the substrate carbonyl, resulting in amide bond cleavage (Fig. 1b) . We 83 reasoned that by designing compounds that targeted this highly conserved Cys residue, we could 84 develop pan-BSH inhibitors. A co-crystal structure of the BSH from Gram positive species 85
Clostridium perfringens and the substrate taurodeoxycholic acid (TDCA) showed that 86 hydrophobic interactions held the bile acid core in place and oriented the amide bond toward the 87 conserved cysteine, leaving the amino acid solvent-exposed (Fig. 1c) .
14 Furthermore, purified C. 88 perfringens BSH tolerates a large degree of variability in the amino acid side chain, including 89 longer chain conjugates. 15 These results suggested that the bile acid D-ring side chain was a 90 possible site for incorporation of electrophilic groups into our inhibitors. 91
Based on this rationale, we designed a small library of potential inhibitors containing 92 both a bile acid core motif to selectively target BSHs and a pendant electrophilic warhead to 93 irreversibly bind the inhibitor to the enzyme (Fig. 1d) . While previous literature suggested that 94 BSH enzymes catalyze amide bond cleavage of all conjugated bile acids regardless of the 95 steroidal core, 1, 8 we recently determined that some species from the abundant Gram negative gut 96 bacterial phylum Bacteroidetes cleave C12 = H but not C12 = OH primary bile acids (Fig. 1a) . 16 
97
As our goal was to develop BSH inhibitors that target both Gram negative and Gram positive 98 strains, we decided to utilize the steroidal portion of the human primary bile acid 99 chenodeoxycholic acid (CDCA, C12 = H) as our scaffold. 100
For the electrophilic trapping groups, we chose warheads that have been successfully deployed 101 in the development of selective and potent protease and kinase inhibitors, 17 and nitrile (6). 23 We also included an inhibitor with an α-fluoromethyl ketone warhead (FMK) 104 (7) in our library. Covalent inhibitors with this warhead have been shown to display high potency 105 and selectivity. [24] [25] [26] In contrast to the more electrophilic α-iodo-, α-bromo-and α-chloromethyl 106 ketone warheads, the weak leaving group ability of fluorine renders the FMK warhead less 107 reactive and and hence more selective. 24, 26, 27 As a result, FMK-based inhibitors have been shown 108 to result in minimal off-target effects.
24,28
109
Biochemical characterization of BSHs 110
Following inhibitor synthesis (Supplementary Note), we next sought to evaluate the 111 activity of inhibitors 1-9 biochemically against both Gram negative and Gram positive BSHs. In 112 particular, we decided to use a selective Bacteroides BSH for inhibitor optimization, reasoning 113 that the more limited substrate scope of this enzyme could make it more difficult to target. We 114 heterologously expressed and purified the selective BSH (BT2086) that we had previously 115 identified in Bacteroides thetaiotaomicron VPI-5482 (B. theta). 16 We then established kinetic 116 parameters for its hydrolysis of conjugated primary and secondary bile acids using a ninhydrin-117 based assay.
29 Consistent with our previous results from B. theta cultures, purified B. theta BSH 118 displayed a preference for TDCA deconjugation and did not deconjugate TCA (Table 1 and 119 Supplementary Fig. 1) . 16 These results suggest that the enzymatic selectivity observed in B. 120 theta culture was due to inherent biochemical properties of the BSH, not to differences in 121 transport or the accessibility of the substrates to the enzyme. 122
We also cloned and expressed the known BSH from the Gram positive strain 123
Bifidobacterium longum SBT2928 BSH 30 and determined the kinetic parameters of this enzyme 124 (Table 1 and Supplementary Fig. 1) . Notably, the K m values for all of the recognized substrates 125 are in the low millimolar range, which is approximately the concentration of these bile acids in 126 the gut. While the k cat values for both enzymes are lower than the k cat reported for the BSH from 127
Lactobacillus salivarius, the K m values for these enzymes are similar to those of previously 128 characterized BSH.
30-32
129
Biochemical evalutation identifies α-FMK compound 7 as lead inhibitor 130
We next evaluated the ability of the compounds in our library to inhibit B. theta and B. 131
longum BSH. We also tested riboflavin (10) and caffeic acid phenethyl ester (CAPE, 11), 132 compounds that had been previously identified in a high throughput screen for inhibition of a 133 BSH from a Lactobacillus salivarius chicken gut isolate. 33 (Fig. 1e) . To determine the BSH 134 inhibitory activity of these compounds, we pre-incubated the B. theta BSH with each inhibitor 135 (100 µM) for 30 minutes and then added a mixture of conjugated bile acids (100 µM final 136 concentration). Hydrolysis of bile acids was monitored by Ultra Performance Liquid 137
Chromatography-Mass Spectrometry (UPLC-MS) over 21 hours. Among the synthesized 138 inhibitors, isothiocyanate (1) displayed modest inhibition. Other compounds containing Michael 139 acceptor warheads (inhibitors 2-6) did not inhibit deconjugation. In contrast, incubation with the 140 α-FMK-based inhibitor 7 resulted in almost complete inhibition of the B. theta BSH activity for 141 21 hours (>98%, Fig. 2a and Supplementary Fig. 2) . In order to validate that the inhibitory 142 activity of compound 7 was due to the presence of fluorine as a leaving group, we synthesized a 143 methyl ketone analog lacking the fluorine atom (8) . 28 This analog did not display BSH inhibition 144 against either recombinant protein or growing B. theta cultures, indicating that the α-fluorine 145 group was necessary for activity ( Fig. 2a and Supplementary Fig. 3 ). Riboflavin did not display 146 any inhibitory activity, while CAPE provided only moderate inhibition of B. theta BSH. 147
We next evaluated the activity of our two most potent inhibitors against B. theta BSH, 148 compounds 1 and 7, as well as CAPE, against the BSH from the Gram positive species B. 149 longum. These compounds displayed similar degrees of inhibition of B. longum BSH as we had 150 observed against B. theta BSH. Compound 7 was again the most active inhibitor, while CAPE 151 was ineffective at inhibiting deconjugation by B. longum BSH at all timepoints ( Fig. 2b and 152 Supplementary Fig. 2 ). These data indicate that compound 7 is a potent inhibitor of purified 153 BSH protein from both a Gram negative and a Gram positive bacterial strain. 154
Compound 7 inhibits BSH activity in growing cultures of gut bacteria 155
Given that compound 7 displayed activity against purified BSHs, we next sought to 156 
162
Bacterial cultures were diluted to pre-log phase and both inhibitor (100 µM) and a 163 mixture of conjugated bile acids (100 µM final concentration) were added simultaneously. 164
Deconjugation was monitored over 24 hours using UPLC-MS. Strikingly, while all six bacterial 165 strains deconjugated bile acids in the presence of vehicle control, we observed almost no 166 deconjugation in any of the cultures grown in the presence of compound 7 (Fig. 2c) . Compound 167 7 did not significantly affect the cell viability of the majority of the tested strains (Fig. 2d) Supplementary Fig. 4) . Taken together, these results indicate that compound 7 is a 172 potent, broad-spectrum inhibitor of BSHs. 173
In contrast, we observed no inhibition of deconjugation over the course of 21 hours in 174 five out of the six bacterial strains grown in the presence of CAPE (100 µM) (Fig. 2c) . CAPE 175 was found to inhibit deconjugation in L. plantarum, suggesting that this compound may inhibit 176
BSHs from Lactobacilli but is not a broad-spectrum BSH inhibitor. Moreover, CAPE inhibited 177 the cell viability of all three Gram negative bacterial strains tested (Fig. 2d , ~200-fold, ~8000-178 fold, and ~4000-fold decreases in 24h CFU/mL compared to DMSO control for B. theta, B. 179 fragilis, and B. vulgatus, respectively). These results suggest that the dominant effect of CAPE 180 on Gram negative bacteria is not inhibition of BSH activity but rather inhibition of growth. 181
Finally, to evaluate our hypothesis that C12 = OH compounds would not be effective 182 broad-spectrum inhibitors, we synthesized a potential inhibitor in which we appended the α-183 FMK warhead to a C12 = OH bile acid core, cholic acid (compound 9, Fig. 1d ). Compound 9 184 displayed significantly reduced ability to inhibit BSH deconjugation in growing B. theta cultures 185 compared to compound 7 (Supplementary Fig. 3 ). These results support the hypothesis that bile 186 acid core structure, specifically C12 substitution, affects the ability of our probes to inhibit 187 selective BSH. In addition, these results suggest that the α-FMK warhead is not broadly reactive 188 but rather requires suitable positioning within the active site, a hypothesis that we further 189 investigated using mass spectrometry and crystallography studies. 190
Compound 7 covalently modifies the catalytic cysteine residue of BSH 191
With the potency of compound 7 established, we next investigated its mechanism of 192 inhibition. The B. theta BSH contains two cysteine residues, Cys2 and Cys67. Analysis of an apo 193 crystal structure of this enzyme revealed that both the cysteine residues are pointed towards the 194 active site, indicating either residue could be a potential site for covalent modification (PDB 195 3HBC). To confirm that compound 7 is a covalent inhibitor that modifies Cys2, we incubated 196 purified BSH enzyme with an excess of this molecule. Analysis by mass spectrometry revealed a 197 mass shift consistent with the addition of a single molecule of compound 7, confirming 198 formation of a covalent bond (Fig. 3a) . Subsequent top-down mass spectrometry analysis 199 identified Cys2 as the modified residue (Fig. 3b) . 200
In order to elucidate the position of the bound inhibitor and guide further inhibitor design, 201
we determined the structure of the B. theta BSH, first in its apo form to 2.7 Å resolution and then 202 covalently bound to compound 7 to 3.5 Å resolution (Supplementary Table 1 
) (PDB XXX). 203
The structure of the BSH-inhibitor complex contains four copies of the protein in the asymmetric 204 unit. The electron density map is best resolved in two of the four subunits, and electron density is 205 clearly visible for the inhibitor in one of these subunits covalently attached to Cys2 (Fig. 3c) . 206
Comparison with the apo structure also suggests that there is a loop (residues 127-138) which 207 repositions to clasp the inhibitor in the active site in a solvent-exposed channel (Supplementary 208 at the catalytic cysteine residue. Furthermore, the co-crystal structure reveals that the C3-210 hydroxyl group is solvent-accessible, suggesting that this site might be amenable to further 211 modification ( Supplementary Fig. 5 ). 212
Compound 7 displays minimal off-target effects 213
While covalent inhibitors have been shown to be highly potent, concerns have been 214 raised that non-specific reactivity of these compounds could result in acute toxicity. 11 Our 215 inhibitors were designed to contain a bile acid core in order to increase selectivity of these 216 compounds for BSHs. However, bile acids are known to be ligands for host nuclear hormone 217 receptors (NhR) and G protein-coupled receptors (GPCR), in particular, the farnesoid X receptor 218 (FXR) and the G protein-coupled bile acid receptor 1 (GPBAR1, or TGR5).
2 In order to 219 determine whether compound 7 could act as a ligand for FXR, we performed an in vitro 220 coactivator recruitment assay. 34 While the known FXR agonist GW4064 showed a clear dose-221 dependent increase in the binding of the co-activator peptide SRC2-2 to FXR (EC 50 = 50 nM), the 222 binding of SRC2-2 to FXR did not increase in the presence of compound 7, suggesting that this 223 inhibitor does not activate FXR (Fig. 4a) . In the presence of GW4064, compound 7 did not 224 display a dose-dependent curve, indicating that compound 7 does not possess FXR antagonist 225 activity at physiologically relevant concentrations (Supplementary Fig. 6 ). Next, we evaluated 226 the effect of compound 7 on TGR5 activation in a human intestinal cell line (Caco-2). 227
Compound 7 did not agonize TGR5 over the range of concentrations tested (Fig. 4b) . In 228 addition, compound 7 did not antagonize TGR5 in the presence of known TGR5 agonist LCA 229 (10 µM) (Supplementary Fig. 6 ). These results suggest that compound 7 does not induce off-230 target effects on either of these critical host receptors. 231
In addition to their effects on host receptors, bile acids are known to be toxic to cells due 232 to their detergent properties. 1, 35 Because the expected in vivo area of action of compound 7 is the 233 lower gut, we tested the toxicity of this compound against human intestinal cells (Caco-2). No 234 resultant toxicity was observed when these cells were incubated with up to 50 µM of compound 235 7 (Fig. 4c) . Because the IC 50 values of compound 7 against bacterial BSHs range from 240 to 236 912 nM, these results suggest that it should be possible to achieve an effective in vivo dose at a 237 concentration that will not result in toxicity to intestinal cells. Taken together, our results indicate 238 that compound 7 is both non-toxic and selective for bacterial BSHs over potential host targets. 239
Compound 7 inhibits BSH activity in conventional mouse feces 240
While we were able to demonstrate the potency of compound 7 against growing cultures 241 of six different strains of gut bacteria, there are hundreds of bacterial species in the human gut. 36 
242
Previous literature had reported significant BSH activity in mouse feces. 37 To further assess 243 whether compound 7 is a pan-inhibitor of BSH, we tested its activity in resuspended feces from 244 conventional mice. Compounds 1, 7, and CAPE (20 µM) were added to a fecal suspension in 245 buffer. After 30 minutes, the deuterated substrate GCDCA-d4 was added, and deconjugation was 246 quantified after 18 hours using UPLC-MS (Fig. 5a) . Strikingly, we observed that incubation with 247 compound 7 completely inhibited the BSH activity in feces (Fig. 5b) . Consistent with our in 248 vitro results, CAPE provided no inhibition of BSH activity in mouse feces. These results 249 demonstrate that compound 7 is a potent, pan-inhibitor of gut bacterial BSH activity. 250
Single dose of compound 7 inhibits BSH activity in conventional mice 251
Having established the potency of compound 7 in vitro, we next sought to evaluate the 252 activity of this inhibitor in conventional mice. C57BL/6 mice were gavaged with a single dose of 253 either compound 7 (10 mg/kg) or vehicle control, and BSH activity was monitored over time in 254 half-day increments until 2.5 days post-gavage (Fig. 5c) . We predicted that if compound 7 was 255 active in vivo, we would observe an initial decrease in BSH activity followed by recovery of 256 activity. Gratifyingly, we observed this expected effect. One day and 1.5 days post-gavage, we 257 noted a significant decrease in BSH activity in feces, while at subsequent timepoints, BSH 258 activity recovered (Fig. 5d) . Consistent with these results, we observed a significant increase in 259 conjugated bile acids and a decrease in deconjugated bile acids 1 day-post gavage. Notably, we 260 observed a decrease in the deconjugated secondary bile acid deoxycholic acid (DCA) at this 261 timepoint (Fig. 5e) . In agreement with our in vitro bacterial cell viability results, we did not 262 observe a significant decrease in bacterial biomass following gavage with compound 7 (Fig. 5f  263 and Supplementary Fig. 7) . Taken together, our results indicate that compound 7 can inhibit gut 264 bacterial BSH activity and modulate the bile acid pool in vivo while not significantly inhibiting 265 overall growth of the gut bacterial community. 266
Discussion 267
In order to uncover the effects that bacterial metabolites have on host health, tools are 268 needed that selectively control the levels of these compounds in fully colonized animals. In this 269 work, we report the development of such a chemical tool, a potent, selective, pan-inhibitor of gut 270 bacterial BSHs. We identified a lead inhibitor, compound 7, that effectively inhibits 271 deconjugation by purified BSH protein, growing cultures of both BSH-containing Gram negative 272
and Gram positive human gut strains, and resuspended conventional mouse feces. We then 273
showed that a single dose of compound 7 administered to conventional mice reduces BSH 274 activity and predictably shifts the in vivo bile acid pool. Importantly, we found that compound 7 275 does not significantly affect the viability of these bacteria. 276
Our results suggest that compound 7 or derivatives thereof can be used as tools to study 277 the biological roles of primary and secondary bile acids in conventional animals, including both 278 wild-type and knock-out mouse strains. These investigations would broaden our understanding 279 of how bile acids affect host immune and metabolic systems and reveal how these metabolites 280 affect the composition and biogeography of the gut bacterial community. 281
In particular, BSH inhibitors could be used to better understand the effects of bile acids 282 on host metabolism. Previous studies have reported conflicting results about how altering BSH 283 activity in vivo may affect host metabolic responses. 37, 39 In these studies, the introduction into 284 the gut of an exogenous bacterial strain overexpressing a heterologous gene or the use of a 285 molecule that may exert metabolic effects through a BSH-independent mechanism do not permit 286 evaluation of how BSH activity affects metabolism in the native host-bacterial system. 287
Moreover, in previous work, we showed that deleting the BSH-encoding gene from B. theta 288 resulted in decreased weight gain and a decreased respiratory exchange ratio in mice colonized 289 with this bacterium compared to mice colonized with the B. theta wild-type strain. 16 However, 290 these experiments were performed in monocolonized germ-free mice and do not reveal how 291 limiting activity of all BSHs will affect the metabolism of conventional animals. Use of a non-292 toxic, pan-BSH inhibitor would enable investigation of how BSH activity directly affects 293 metabolism in fully colonized hosts. 294
In addition, BSH inhibitors could enable investigation of how bile acids affect host 295 immune response in the context of liver cancer. A recent study proposed a causal connection 296 between the conversion of primary to secondary bile acids and a decrease in a tumor-suppressive 297 environment in the liver mediated by the accumulation of beneficial NKT cells. 40 Use of a BSH 298 inhibitor in mouse models of liver cancer could further test this hypothesis by shifting the 299 endogenous in vivo bile acid pool toward primary bile acids without significantly perturbing the 300 enterohepatic system and the microbial community. 301
Finally, because BSH inhibitors would remove secondary bile acids from the bile acid 302 pool, such inhibitors could be used in chemical complementation experiments in which 303 individual secondary bile acids were reintroduced through feeding. These studies would reveal 304 how specific secondary bile acids affect host physiology and bacterial community composition in 305 conventional animals. Looking ahead, if use of BSH inhibitors in vivo beneficially affects host 306 physiology, by limiting liver tumor growth, for example, or decreasing liver steatosis, these 307 compounds could be developed as novel drug candidates. In this way, development of 308 mechanism-based, non-toxic chemical probes for bacterial enzymes could lay the groundwork 309 for potential therapeutic agents that target the microbiome. TDCA, 25 µM each) were added to bacterial cultures at OD 600 0.1. Bacterial cultures were 367 allowed to grow into stationary phase and percent deconjugation at 24h was determined by 368
UPLC-MS. (d) Compound 7 is not bactericidal. Bacterial strains were incubated with conjugated 369
bile acids (as described in panel a) and compound (100 µM) and plated at 24h to assess the 370 viability of each strain. CAPE decreased the cell viability of the Gram negative strains tested. 371
Red downward arrows indicate fold decrease compared to DMSO control. For (c) and (d), one-372 way ANOVA followed by Dunnett's multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001, 373 ****p<0.0001, ns = not significant. All assays were performed in biological triplicate, and data 374 are presented as mean ± SEM. 375 electron density visible at the active site of one of the four subunits in the asymmetric unit, 386 consistent with the conclusion that the inhibitor is covalently attached to Cys2. Panel C was 387 prepared using PYMOL software (Schroedinger). 388 
Online Methods 421
Reagents. All bile acids were commercially purchased from Steraloids Inc. and Sigma Aldrich. pre-formed Ni-NTA for 45 mins at 4 °C. The slurry was loaded onto a column and allowed to 447 drain under gravity. The nickel-bound protein was eluted with buffer (50 mM sodium phosphate 448 at pH 7.5, 300 mM NaCl, 0.25 mM TCEP, 5% glycerol) containing gradually increasing 449 concentration of imidazole. Collected fractions were tested for purity by SDS-PAGE. The pure 450 fractions were combined and concentrated followed by dialysis using the storage buffer (50 mM 451 sodium phosphate at pH 7.5, 300 mM NaCl, 0.25 mM TCEP and 5% glycerol). 452
For crystallization purposes, the protein was further purified using S200 size exclusion column 453 (from GE) on a BioRad FPLC in 50 mM tris(hydroxymethyl)aminomethane buffer with 300 mM 454 NaCl, 0.25 mM TCEP and 5% glycerol at pH 7.5. 455 B. adolescentis rBSH. Recombinant BSH from B. adolescentis SBT2928 was expressed and 456 purified as above, except 0.25 mM IPTG was used for protein expression and 1 mM TCEP for 457 protein purification. 458
Enzyme Kinetics. The enzyme was characterized using a modified BSH activity assay. 29 To 459 144.8 µL reaction buffer (PBS at pH 7.5 containing 10 mM TCEP and 5% glycerol), 35.2 µL of 460 recombinant BSH was added as a solution in PBS at pH 7.5 containing 0.25 mM TCEP and 5% 461 glycerol to afford a final concentration of 6.2 µM and 7.0 µM for B. theta BSH and B. longum 462 BSH, respectively. This solution was preheated to 37 °C in a water bath. 20 µL of a conjugated 463 bile acid in DMSO at appropriate concentration was preheated to 37 °C in a water bath and 464 adolescentis were diluted to an OD 600 of 0.1 in 2 mL fresh CHG containing 100 µM TUDCA or 490 TDCA, respectively, and inhibitor 7 at various concentrations. B. theta and B. adolescentis 491 deconjugated TUDCA and TDCA, respectively, to the greatest extent of any of the conjugated 492 substrates in the Inhibitor Screen in Bacteria assay, and therefore these substrates were used to 493 determine IC 50 values. Cultures were then allowed to grow anaerobically at 37 °C for 24h (B. 494 adolescentis) or 48h (B. theta). Longer incubation time was required for B. theta because for this 495 bacterium, significant BSH activity was only observed during stationary phase. Cultures were 496 extracted and analyzed as per the method described in "Inhibitor screen using rBSH". 497
Crystallization, Data Collection, and Structure Determination. Crystals of BSH and BSH in 498 complex with compound 7 were grown in 24-well format hanging drops at room temperature. 499 BSH crystals (5 mg/mL) grew from micro seeding after 3 days in 42% tacimate 100 mM Tris pH 500 7.4. The BSH-compound 7 complex (5.0 mg/mL) crystals grew after 5 d in 21% PEG 3350 and 501 100 mM X Sodium citrate tribasic dihydrate pH 5.0. Crystals were cryoprotected by 502 supplementing the mother liquor with 10% 2-methyl-2,4-pentanediol (v/v). Individual crystals 503
were flash frozen in liquid nitrogen and stored until data collection. Data collection was 504 performed at Advanced Photon Source NE-CAT beamline 24 ID-C. Diffraction images were 505 processed and scaled using XDS. 41 To obtain phases for the apo BSH structure, molecular 506 NCS restraints, optimization for X-ray/stereochemistry weights, and optimization for X-ray/ADP 511 weights. The BSH-compound 7 structure was phased using molecular replacement for all four 512 copies in the asymmetric unit with the apo BSH as a search model. Iterative model building and 513 refinement for the BSH-compound 7 was similar to the apo BSH structure with changes to 514 grouping atomic B-factors and the addition of an applied twinlaw of k h -l. Model quality for 515 both structures was evaluated using composite omit density maps. In final cycles of model 516 building, NCS restraints were removed. Final model quality was assessed using MolProbity. 45 
517
All crystallographic data processing, refinement, and analysis software was compiled and 518 supported by the SBGrid Consortium. 46 Data acquisition and refinement statistics are presented 519 in Supplementary Table 1. Figures were prepared using Pymol (Schrödinger). 520
Mass Spectrometry Analysis. BSH protein was incubated with DMSO or a 10-fold molar 521 excess of inhibitor 7 for 2 hours at room temperature. Reactions were then analyzed by LC-MS 522 using a Shimadzu LC and autosampler system (Shimadzu, Marlborough, MA) interfaced to an 523 LTQ ion trap mass spectrometer (ThermoFisher Scientific, San Jose, CA). Protein (5 ug) was 524 injected onto a self-packed RP column (5 cm POROS 50R2, Applied Biosystems, Foster City, 525 CA), desalted for 4 minutes with 100%A, eluted with a ballistic gradient (0-100% B in 1 minute; 526 A= 0.2 M acetic acid in water, B= 0.2M acetic acid in acetonitrile), and introduced to the mass 527 spectrometer by ESI (spray voltage = 4.5 kV). The mass spectrometer was programmed to 528 collect full scan mass spectra in profile mode (m/z 300-2000). Mass spectra were deconvoluted 529 using MagTran version 1.03b2. 47 
530
To determine the site of modification, compound 7 modified protein was analyzed as 531 described above, except that the LC system was interfaced to an Orbitrap Lumos Mass 532 Spectrometer (ThermoFisher Scientific). The mass spectrometer was programmed to perform 533 GlutaMAX and Earle's Salts (Gibco, Life Technologies, UK). All cell culture media were 550 supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100µg/ml 551 streptomycin (GenClone). Cells were grown in FBS-and antibiotic-supplemented 'complete' 552 media at 37°C in an atmosphere of 5% CO 2 . 553
Cell Viability Assay. Caco-2 cells were treated with compound 7 diluted in DMSO in complete 554 MEM media. The concentration of DMSO was kept constant and used as a negative control. instructions. Plasmid transfections were performed in antibiotic-free MEM media with 10% 567 FBS. After overnight incubation, compound 7 and/or bile acids were added in complete media. 568
Compound 7 and/or bile acids were diluted in DMSO and the concentration of DMSO was kept 569 constant. 10 µM of LCA was added along with compound 7 to study TGR5 antagonism and 570 incubated overnight. Cells were harvested the next day for luciferase assay. 571
Luciferase Reporter Assay. Luminescence was measured using the Dual-Luciferase Reporter 572
Assay System (Promega Corporation) according to manufacturer's instructions. Cells were 573 washed gently with PBS and lysed in PLB from the kit. Matrigel-attached cells were scraped in 574 PLB. Luminescence was measured using a SpectraMax M5 plate reader (Molecular Devices, San 575
Jose, CA) at the ICCB-Longwood Screening Facility at HMS. Luminescence was normalized to 576
Renilla luciferase activity and percentage relative luminescence was calculated compared to 577 DMSO control. 578
Screen of Inhibitors in Conventional Mouse
Feces. BSH activity in fecal pellets were 579 quantified using a modified version of a published method. 49 Fecal pellets (approximately 10-20 580 mg) were broken into fine paticles in buffer (10% PBS, 90% sodium acetate at pH 5.2) to obtain 581 a concentration of 1 mg/mL. 20 µM of inhibitors and CAPE were added to the fecal slurry and 582 the mixture was incubated at 37 °C for 30 mins. 100 µM glycochenodeoxycholic acid-d4 583 (GCDCA-d4) was then added to the mixture and the mixture was incubated at 37 °C for 18 584 hours. The tubes were then frozen in dry ice for 5 mins and upon thawing were diluted with an 585 equal volume of methanol. The slurry was then centrifuged at 12,500g for 10 mins. The 586 supernatant was decanted into a clean Eppendorf tube and centrifuged again. The supernatant 587 was then transferred to MS vials and analyzed by UPLC-MS using a previously published 588 method. 16 
589
Animal Studies. C57BL/6 mice obtained from Jackson laboratories were maintained under a 590 strict 12 h/12h light/dark cycle and a constant temperature (21 ± 1 °C) and humidity (55-65%). 591
All experiments were conducted on 8-9 week old male mice. The mice were maintained on a 592 standard chow diet (LabDiet, no. 5053) for the duration of the experiment. Mice were split into 593 two groups of four mice each. The vehicle group were gavaged with 200 µL of corn oil 594 containing 5% DMSO. The experimental group were gavaged with 200 µL of corn oil containing 595 compound 7 at a concentration of 1.25 mg /mL. For the fecal pellet collection, each mouse was 596 transferred to a temporary cage for a few minutes until it defecated. Once these fresh fecal pellets 597 were collected, the mice were transferred back to their home cages. All experiments involving 598 mice were performed using IACUC approved by the Beth Israel Deaconess Medical Center. 599 BSH Activity in Feces. BSH activity in fecal pellets were quantified using a modified version of 600 a published method. 49 Fecal pellets (approximately 10-20 mg) were suspended in buffer (10% 601 PBS, 90% sodium acetate at pH 5.2) containing 100 µM glycochenodeoxycholic acid-d4 602 (GCDCA-d4) to obtain a concentration of 20 mg/mL. The fecal pellets were broken into fine 603 particles and the mixture was incubated at 37 °C for 25 mins. Samples were analyzed as per the 604 method described in "Screen of Inhibitors in Conventional Mouse Feces. 605
Quantification of Fecal Bile Acids. Bile acid extraction and analysis of pre-massed fecal pellets 606 (~10-20 mg/sample) was performed using a previously published method. 
